AstraZeneca PLC CEDEAR (AZN)
BCBA
64,650.00
+700.00 (+1.09%)
Closed
Oct 7, 2026
Day's Range
64,325.0064,950.00
52 wk Range
54,750.0080,275.00
Financial Statements - AZN - AstraZeneca PLC CEDEAR
Revenue
58.73B▼ 99.9%
Net Income
10.23B▼ 99.9%Net Margin 17.4%
EBITDA
19.13B▼ 99.9%
Free Cash Flow
8.67B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 58.73B | 75.93T | 45.81B | 44.35B | 37.41B | 26.61B |
| Cost of Goods | 10.63B | 14.33T | 8.26B | 12.39B | 12.43B | 5.29B |
| Gross Profit | 48.10B | 61.59T | 37.54B | 31.96B | 24.98B | 21.31B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 13.32B | 14.39T | 7.16B | 4.51B | -139M | 3.91B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 12.40B | 12.20T | 6.89B | 2.50B | -265M | 3.91B |
| Income Tax | 2.16B | 2.31T | 938M | -792M | -380M | 772M |
| Net Income | 10.23B | 9.88T | 5.96B | 3.29B | 115M | 3.14B |
| EPS Basic | 6.6 | 4.54 | 3.84 | 2.12 | 0.08 | 2.44 |
| EPS Diluted | 6.54 | 4.5 | 3.81 | 2.11 | 0.08 | 2.44 |
| Basic Shares Outstanding | 1.55B | 2.17T | 1.46M | 1.46M | 1.34M | 1.24M |
| Diluted Shares Outstanding | 1.55B | 2.17T | 1.46M | 1.46M | 1.34M | 1.24M |
| Ebit | 14.01B | 14.56T | 8.52B | 3.83B | 1.01B | 5.18B |
| Ebitda | 19.13B | 21.89T | 12.88B | 9.82B | 3.92B | 6.83B |
| Net Income Continuous Operations | 12.40B | 12.20T | 6.89B | 2.50B | -265M | 3.91B |
| Minority Interests | -8M | -6M | -6M | -5M | -3M | 52M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
